{
    "clinical_study": {
        "@rank": "78907", 
        "arm_group": {
            "arm_group_label": "DCVax-Direct", 
            "arm_group_type": "Experimental", 
            "description": "DCVax-Direct: autologous, activated dendritic cells for intratumoral injection"
        }, 
        "brief_summary": {
            "textblock": "The study comprises a Phase I component during which the optimal dose of DCVax-Direct for\n      the treatment of solid tissue tumors will be identified, followed by a Phase II component to\n      determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability\n      to reduce tumor growth."
        }, 
        "brief_title": "Safety and Efficacy Study of DCVax-Direct in Solid Tumors", 
        "condition": [
            "Locally Advanced Tumor", 
            "Metastatic Solid Tissue Tumors", 
            "Liver Cancer", 
            "Colorectal Cancer", 
            "Pancreatic Cancer", 
            "Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Liver Neoplasms", 
                "Melanoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (summary):\n\n          -  Age between 18 and 75 years (inclusive) at screening.\n\n          -  Karnofsky performance status (KPS) of 60 or higher or Eastern Cooperative Oncology\n             Group (ECOG) 0-2 at screening.\n\n          -  Patients with a histological or cytopathological confirmed diagnosis of a locally\n             advanced or metastatic solid tumor malignancy for which standard treatment is no\n             longer effective or does not offer curative or life-prolonging potential per\n             clinician judgment.\n\n          -  Not eligible for complete resection due to either, tumor location, physician's\n             assessment or patient's choice.\n\n          -  Must have completed at least one and no more than four treatment regimens in the\n             metastatic or advanced setting in the disease currently under treatment to reduce\n             tumor burden. Treatment must have been discontinued at least 14 days prior to\n             initiating leukapheresis.\n\n          -  Any steroid therapy >2 mg dexamethasone or equivalent dose should be stopped or have\n             been tapered down 2 weeks prior to the leukapheresis.\n\n          -  At least one measurable tumor mass, i.e. a lesion that can accurately be measured by\n             CT/MRI in at least one dimension with longest diameter \u2265 1 cm, that is accessible for\n             injection either with or without imaging (CT/ultrasound) guidance.\n\n          -  Adequate hematological, hepatic, and renal function,\n\n          -  Adequate blood coagulation parameters\n\n          -  Life expectation of >3 months.\n\n        Exclusion Criteria (Summary):\n\n          -  Positive HIV-1, HIV-2, or Human T-lymphotropic virus (HTLV-I/II) tests.\n\n          -  History of current or prior (within the last two years) active clinically significant\n             malignancy other than the tumor type for which DCVax-Direct treatment is considered ,\n             and except for adequately treated basal cell or squamous cell skin cancer or in situ\n             cervical cancer.\n\n          -  Presence of brain metastases, unless treated surgically and/or irradiated and\n             clinically stable off steroids or on low dose (< 2 mg per day) steroids for \u2265 14\n             days, or presence of leptomeningeal disease.\n\n          -  History of immunodeficiency or unresolved autoimmune disease.\n\n          -  Requirement for ongoing immunosuppressants.\n\n          -  Prior active immunotherapy for cancer within the past 2 years.\n\n          -  Ongoing medical need for continuous anti-coagulation or anti-platelet medication.\n\n          -  Known genetic cancer-susceptibility syndromes.\n\n          -  Acute or active uncontrolled infection\n\n          -  Ongoing fever \u2265 101.5 degrees F/38.6 degrees C at screening.\n\n          -  Unstable or severe intercurrent medical conditions such as unstable angina,\n             uncontrolled arrhythmias, Crohn's Disease, ulcerative colitis etc.\n\n          -  Females of child-bearing potential who are pregnant or lactating or who are not using\n             adequate contraception (surgical, hormonal or double barrier, i.e. condom and\n             diaphragm).\n\n          -  Allergy or anaphylaxis to any of the reagents used in this study.\n\n          -  Inability to obtain informed consent because of psychiatric or complicating medical\n             problems.\n\n          -  Inability or unwillingness to return for required visits and follow-up exams."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882946", 
            "org_study_id": "NWBio 050012"
        }, 
        "intervention": {
            "arm_group_label": "DCVax-Direct", 
            "description": "Autologous, activated dendritic cells for intratumoral injection", 
            "intervention_name": "DCVax-Direct", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Mollie.Geismer@orlandohealth.com", 
                    "last_name": "Mollie Geismer, RN, PhD, CCRP"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "MD Anderson Cancer Center Orlando"
                }, 
                "investigator": {
                    "last_name": "Omar Kayaleh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bsaigal@mdanderson.org", 
                    "last_name": "Babita Saigal, MD", 
                    "phone": "713-745-8618"
                }, 
                "contact_backup": {
                    "last_name": "Patient Access Center", 
                    "phone": "713-792-1160"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Vivek Subbiah, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS", 
        "other_outcome": [
            {
                "measure": "Number of patients surviving", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Number of patients surviving without tumor progression", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "overall_official": {
            "affiliation": "Northwest Biotherapeutics", 
            "last_name": "Marnix Bosch, MBA, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients with tumor response", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "Northwest Biotherapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Northwest Biotherapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}